Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

NCT07107217 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Camrelizumab
DRUG: Doxorubicin +cyclophosphamide+ filgrastimum
DRUG: carboplatin + paclitaxel (CP)

Sponsor

Blokhin's Russian Cancer Research Center